Androgen Deprivation Therapy News and Research

RSS

Research characterizes iPS87 cell line as cancer-inducing, stem cell-like cell line

Oncotarget Volume 11, Issue 12 reported outside its natural niche, the cultured prostate cancer stem cells lost their tumor-inducing capability and stem cell marker expression after approximately 8 transfers at a 1:3 split ratio.

27 Mar 2020

Highly focused radiation may slow disease progression in men with oligometastatic prostate cancer

Highly focused, intense doses of radiation called stereotactic ablative radiation (SABR) may slow progression of disease in a subset of men with hormone-sensitive prostate cancers that have spread to a few separate sites in the body, according to results of a phase II clinical trial of the therapy.

26 Mar 2020

Intense and targeted radiotherapy could slow progression of certain prostate cancers

Targeted and strong doses of stereotactic ablative radiation (SABR) radiotherapy could slow progression in prostate cancer.

26 Mar 2020

Exercise works for prostate cancer sufferers starting treatment

A James Cook University researcher says scientists have found that exercise can be beneficial to patients as they begin treatment for prostate cancer.

11 Mar 2020

NCCN publishes recommendations for assessing quality improvements in cancer care

The National Comprehensive Cancer Network has published a curated list of high-impact measures for assessing quality improvements in cancer care.

10 Mar 2020

Statin use alone or with metformin may increase survival in high-risk prostate cancer patients

Among high-risk prostate cancer patients - those with high PSA and Gleason scores of 8 or more - many will develop a difficult-to-treat disease.

10 Feb 2020

Study evaluates the impact of prostate cancer treatment decisions

A five-year follow-up study of more than 2,000 U.S. men who received prostate cancer treatment is creating a road map for future patients regarding long-term bowel, bladder and sexual function in order to clarify expectations and enable men to make informed choices about care.

27 Jan 2020

Researchers uncover genetic anomaly linked with poor response to common asthma treatment

A new Cleveland Clinic study has uncovered a genetic anomaly associated with poor response to a common asthma treatment.

13 Jan 2020

Short-term exercise could help to reduce side-effects of prostate hormone therapy

A prescription of short-term exercise for patients with advanced prostate cancer could help to reduce the side-effects of hormone therapy, according to new research from the University of East Anglia.

9 Dec 2019

Prostate cancer 'super responders' could live for two years or more on immunotherapy

Some men with advanced prostate cancer who have exhausted all other treatment options could live for two years or more on immunotherapy, a major clinical trial has shown.

27 Nov 2019

New oral androgen deprivation therapy increases risk of death in cardiovascular patients

A new large population-based study from the Sidney Kimmel Cancer Center – Jefferson Health shows that novel oral androgen signaling inhibitor therapies are associated with an increased risk of death in patients with pre-existing cardiovascular conditions.

13 Aug 2019

Researchers identify key to controlling growth and progression of prostate cancer

Cancer researchers at the University of Virginia School of Medicine have identified a key to controlling the growth and progression of prostate cancer, the second most common cancer in men.

30 Jul 2019

Could hormone therapy for prostate cancer increase the risk of Alzheimer’s disease?

Men who take hormone-blocking therapy (ADT) for prostate cancer may be at an increased risk of developing dementia and Alzheimer’s disease.

8 Jul 2019

Androgen receptor plays vital role in regulating multiple mitochondrial processes

Androgens, commonly known as male hormones, stimulate prostate cancer cells to grow. Thus, many of the drugs to target that cancer focus on stopping androgen biosynthesis or blocking the androgen receptor. This standard treatment is known as androgen deprivation therapy.

20 Mar 2019

Hormonal treatment associated with depression in men with prostate cancer

Men who receive anti-hormonal treatment after having their prostate removed are 80% more likely to suffer from depression than men who don't receive this treatment. This leads researchers to suggest that patients receiving androgen deprivation therapy should be monitored for post-surgical depression.

18 Mar 2019

Aggressive prostate cancer linked to hereditary breast cancer, confirms study

Aggressive prostate cancer, one of the leading causes of cancer deaths in men, is associated with BRCA2 mutations, which are also linked to hereditary breast cancer, ovarian cancer and pancreas cancer, among others.

10 Jan 2019

Study defines biomarker in response to treatment of castration-resistant prostate cancer

The most aggressive type of prostate cancer, castration-resistant prostate cancer, can be treated with two different therapies: taxanes or hormone treatment. Until this day there are no comparative studies between the two and the decision on which treatment to use is done empirically and based on the patient's preferences.

14 Nov 2018

Prostate cancer patients receiving androgen deprivation therapy may have higher heart failure risk

Androgen deprivation therapy was associated with a 72 percent higher risk of heart failure in a study of patients with prostate cancer.

7 Nov 2018

Radiotherapy combined with androgen-deprivation therapy improves overall survival up to 10 years

The long-term follow up of the NRG Oncology trial RTOG 9408, studying the addition of short-term androgen-deprivation therapy (ADT) to radiotherapy (RT) for men with early, localized prostate adenocarcinoma, indicated that RT combined with ADT is superior to RT alone for overall survival up to 10.4 years following treatment.

23 Oct 2018

Prostate radiotherapy improves survival in men with low burden of metastatic disease

Radiotherapy to the prostate improves overall survival in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden but not in those with higher burden of disease, according to results from a pre-planned analysis of a large comparison study reported at ESMO 2018.

22 Oct 2018